TS
AVTX icon

Tamar Securities’s Avalo Therapeutics AVTX Stock Holding History

Tamar Securities’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8
Closed -$17K – 56
2022
Q1 		$17K Hold
8
– – ﹤0.01% 60
2021
Q4 		$39K Hold
8
– – 0.01% 59
2021
Q3 		$50K Hold
8
– – 0.02% 51
2021
Q2 		$75K Hold
8
– – 0.03% 50
2021
Q1 		$70K Hold
8
– – 0.03% 55
2020
Q4 		$61K Hold
8
– – 0.03% 44
2020
Q3 		$53K Hold
8
– – 0.03% 43
2020
Q2 		$60K Buy
+8
New +$58.1K 0.05% 43

Other funds holding AVTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tamar Securities's AVTX Position: Q2 2022 in Review

Tamar Securities sold out of Avalo Therapeutics (AVTX) in Q2 2022, closing a stake of 8 shares — an estimated $17K sold.

Tamar Securities first reported a position in AVTX in Q2 2020 and held it in 8 quarters. The position peaked at $75K in Q2 2021. 43 funds tracked by Wall St. Rank hold AVTX as of Q2 2022.

  • Tamar Securities reported no remaining Avalo Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Tamar Securities sold 8 Avalo Therapeutics shares in Q2 2022, an estimated $17K.
  • Tamar Securities first reported a position in Avalo Therapeutics in Q2 2020 and held it in 8 quarters.
  • Tamar Securities's Avalo Therapeutics position peaked at $75K in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2022.

Based on Tamar Securities's 13F filing for Q2 2022, filed 5 Aug 2022.